<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02948582</url>
  </required_header>
  <id_info>
    <org_study_id>EP-101-02</org_study_id>
    <secondary_id>2010-018987-17</secondary_id>
    <nct_id>NCT02948582</nct_id>
  </id_info>
  <brief_title>Assessment of the Safety and Ability of a Once-a-day Dose of an Orally Inhaled Medicine [i.e., Glycopyrrolate Inhalation Solution = GIS] to Improve Airflow in the Lungs When Delivered Using an eFlow Nebulizer in Patients With Chronic Obstructive Pulmonary Disease (COPD)</brief_title>
  <official_title>Randomized, Placebo-Controlled, Double-Blind, Dose Ranging, Single-Dose, 6-Way Crossover Study to Assess Safety, Efficacy and Pharmacokinetics of EP-101 Using eFlow Nebuliser in Patients With COPD</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sunovion Respiratory Development Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sunovion Respiratory Development Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study assessed the safety and ability of an orally inhaled medicine [i.e., Glycopyrrolate
      Inhalation Solution = GIS] to improve airflow in the lungs when delivered using an eFlow
      nebulizer in 42 patients with Chronic Obstructive Pulmonary Disease (COPD). Each patient
      randomly received several, single doses of GIS, or placebo, separated by approximately 1 to 2
      weeks. After the dose was given, lung airflow was measured over 24 hours and blood was
      collected to measure how much GIS was in the bloodstream. The study was conducted to find the
      once-a- day GIS dose that produced the highest improvement in lung airflow using the eFlow
      nebulizer.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2010</start_date>
  <completion_date type="Actual">November 2010</completion_date>
  <primary_completion_date type="Actual">November 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Trough FEV1 (Change From Baseline)</measure>
    <time_frame>24hr post dose</time_frame>
    <description>Spirometry measurements were conducted in accordance with the current ATS/ERS 2005 guidelines.
Trough FEV1 was defined as the mean of FEV1 values obtained at 23 hours 30 minutes and 24 hours post-dose of each Treatment Visit.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Standardized FEV1AUC0-12 Area Under the FEV1 Curve From 0 to 12 Hours Post-dose ( Actual and Change From Baseline).</measure>
    <time_frame>0-12h post dose</time_frame>
    <description>Spirometry measurements were conducted in accordance with the current ATS/ERS 2005 guidelines.. The standardized actual FEV1 AUC(0-12) was calculated using the trapezoidal rule divided by the actual hours from the first FEV1 to the last FEV1 in the interval. Standardized change from baseline FEV1 AUC(0-12) was also calculated similarly, using the change from pre-dose FEV1.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Standardized FEV1AUC12-24 Area Under the FEV1 Curve From 12 to 24 Hours Post- Dose (Actual and Change From Baseline).</measure>
    <time_frame>12-24h post dose</time_frame>
    <description>Spirometry measurements were conducted in accordance with the current ATS/ERS 2005 guidelines. The standardized actual FEV1 AUC(12-24) was calculated using the trapezoidal rule divided by the actual hours from the first FEV1 to the last FEV1 in the interval. Standardized change from baseline FEV1 AUC(12-24) was also calculated similarly, using the change from pre-dose FEV1.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Standardized FEV1 AUC0-24 Area Under the FEV1 Curve From 0 to 24 Hours Post-dose (Actual and Change Baseline)</measure>
    <time_frame>0 to 24h</time_frame>
    <description>Spirometry measurements were conducted in accordance with the current ATS/ERS 2005 guidelines. . The standardized actual FEV1 AUC(0-24) was calculated using the trapezoidal rule divided by the actual hours from the first FEV1 to the last FEV1 in the interval. Standardized change from baseline FEV1 AUC(0-24) was also calculated similarly, using the change from pre-dose FEV1.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Peak FEV1 (Change From Baseline and Percent Change)</measure>
    <time_frame>0-4h post dose</time_frame>
    <description>spirometry measurements were conducted in accordance with the current ATS/ERS 2005 guidelines. . The peak FEV1 was defined as the highest post-dose FEV1 value within 4 hrs after the dose. Percent change from baseline was calculated as 100 times the difference of peak FEV1 minus baseline FEV1 divided by baseline FEV1.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cmax; Maximum Observed Plasma Concentration</measure>
    <time_frame>0 to 12 hour</time_frame>
    <description>Pk parameters are calculated from glycopyrrolate plasma concentration analysed from serial blood samples collected between 0 and 12 hr</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax; Time to Maximum Observed Plasma Concentration</measure>
    <time_frame>0 to 12 hours</time_frame>
    <description>Pk parameters are calculated from glycopyrrolate plasma concentration analysed from serial blood samples collected between 0 and 12 hr</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>t1/2; Plasma Half-life</measure>
    <time_frame>0 to 12 hour</time_frame>
    <description>Pk parameters are calculated from glycopyrrolate plasma concentration analysed from serial blood samples collected between 0 and 12 hr</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC0-t; Area Under the Plasma Concentration-time Curve From Time Zero to Time of Last Measurable Drug Concentration.</measure>
    <time_frame>0 to 12 hour</time_frame>
    <description>Pk parameters are calculated from glycopyrrolate plasma concentration analysed from serial blood samples collected between 0 and 12 hr</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC0-inf Area Under the Plasma Concentration-time Curve From Time Zero to Infinity</measure>
    <time_frame>0 to 12 hour</time_frame>
    <description>Pk parameters are calculated from glycopyrrolate plasma concentration analysed from serial blood samples collected between 0 and 12 hr</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Who Died, Number of Subjects With Treatment Emergent SAEs, Number of Subjects Who Discontinued Due to AE</measure>
    <time_frame>Day 69 (includes dosing Day 1, washout Day 12, safety follow up Day 69)</time_frame>
    <description>AE's are defined as existing conditions which worsen or events which occur during the course of the clinical trial after treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Clinically Significant Abnormal Vital Signs Reported During the Study</measure>
    <time_frame>0-24 h</time_frame>
    <description>Vital signs were measured at screening and at each Treatment Visit pre-dose (within 30 minutes prior to dose); post-dose at 30 minutes and 1, 2, 4, 8, 12 and 24 hours; and then at the post study assessment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Clinically Significant Abnormal Laboratory Results Reported During the Study</measure>
    <time_frame>Day -14, Day 69</time_frame>
    <description>Clinical safety lab parameters were collected at screening and at the post study assessment. Any laboratory values that were out of range of normal reference values were evaluated by the Investigators.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Clinically Significant ECG Parameters Reported During the Study</measure>
    <time_frame>0 to 24h</time_frame>
    <description>ECGs were recorded at screening and at each study treatment visit pre-dose (within 30 minutes prior to dose); post-dose at 30 minutes and 1, 2, 4, 8, 12 and 24 hours; and then at the post study assessment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Subjects With Treatment Emergent AEs</measure>
    <time_frame>Day 69 (includes dosing Day 1, washout Day 12, safety follow up Day 69)</time_frame>
    <description>AE's are defined as existing conditions which worsen or events which occur during the course of the clinical trial after treatment</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">42</enrollment>
  <condition>Chronic Obstructive Pulmonary Disease</condition>
  <arm_group>
    <arm_group_label>Glycopyrrolate Inhalation Solution12.5μg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Glycopyrrolate Inhalation Solution12.5μg via e-flow nebulizer, once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Glycopyrrolate Inhalation Solution 50μg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Glycopyrrolate Inhalation Solution 50mg via e-flow nebulizer, once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Glycopyrrolate Inhalation Solution 100μg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Glycopyrrolate Inhalation Solution 100μg via e-flow nebulizer, once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Glycopyrrolate Inhalation Solution 200μg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Glycopyrrolate Inhalation Solution 200μg via e-flow nebulizer, once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Glycopyrrolate Inhalation Solution 400μg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Glycopyrrolate Inhalation Solution 400μg via e-flow nebulizer, once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo 0.5mL</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo 0.5mL via e-flow nebulizer, once daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Glycopyrrolate Inhalation Solution12.5μg</intervention_name>
    <description>Glycopyrrolate Inhalation Solution12.5μg via eFlow, once daily</description>
    <arm_group_label>Glycopyrrolate Inhalation Solution12.5μg</arm_group_label>
    <other_name>GIS</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Glycopyrrolate Inhalation Solution 50μg</intervention_name>
    <description>Glycopyrrolate Inhalation Solution 50μg via eFlow, once daily</description>
    <arm_group_label>Glycopyrrolate Inhalation Solution 50μg</arm_group_label>
    <other_name>GIS</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Glycopyrrolate Inhalation Solution 100μg</intervention_name>
    <description>Glycopyrrolate Inhalation Solution 100μg via eFlow, once daily</description>
    <arm_group_label>Glycopyrrolate Inhalation Solution 100μg</arm_group_label>
    <other_name>GIS</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Glycopyrrolate Inhalation Solution 200μg</intervention_name>
    <description>Glycopyrrolate Inhalation Solution 200μg via eFlow, once daily</description>
    <arm_group_label>Glycopyrrolate Inhalation Solution 200μg</arm_group_label>
    <other_name>GIS</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Glycopyrrolate Inhalation Solution 400μg</intervention_name>
    <description>Glycopyrrolate Inhalation Solution 400μg via eFlow, once daily</description>
    <arm_group_label>Glycopyrrolate Inhalation Solution 400μg</arm_group_label>
    <other_name>GIS</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo 0.5mL</intervention_name>
    <description>Placebo 0.5mL via eFlow, once daily</description>
    <arm_group_label>Placebo 0.5mL</arm_group_label>
    <other_name>Placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male and female patients aged 40 through 75 years, inclusive

          2. A clinical diagnosis of COPD according to the GOLD guidelines

          3. Current smokers or ex-smokers with at least 10 pack-year smoking history (e.g., at
             least 1 pack/day for 10

          4. Post-bronchodilator FEV1 30-70% of predicted normal at the Screening Visit

          5. Post-bronchodilator FEV1/FVC ratio &lt; 0.70 at the Screening Visit

          6. Improvement in FEV1 &gt;12% and 150 mL following inhalation of ipratropium bromide at the
             Screening Visit

          7. Ability to perform reproducible spirometry according to the ATS/ERS guidelines

          8. Willing to stay at the study site for approximately 30 hours on each treatment visit

          9. Willing and able to provide written informed consent

        Exclusion Criteria:

          1. Females who are pregnant or lactating at the Screening Visit, or if of childbearing
             potential not using one of the following acceptable means of birth control throughout
             the study:

               -  Abstinence

               -  Post-menopausal for at least two years

               -  Surgically sterile (i.e., tubal ligation, hysterectomy)

               -  Oral contraceptives (taken for at least one month prior to the Screening Visit)

               -  Approved implantable or injectable contraceptives (e.g., Norplant®, Depo-Provera®
                  or equivalent)

               -  Barrier methods (e.g., condoms with spermicide)

               -  Intrauterine device (i.e., IUD)

               -  Vasectomy of male partner

               -  Non-heterosexual life style

          2. Current evidence or recent history of any clinically significant disease (other than
             COPD) or abnormality in the opinion of the Investigator that would put the subject at
             risk or which would compromise the quality of the study data; including but not
             limited to cardiovascular disease, myocardial infarction, cardiac failure,
             uncontrolled hypertension, life-threatening arrhythmias, uncontrolled diabetes,
             neurologic or neuromuscular disease, liver disease, gastrointestinal disease or
             electrolyte abnormalities

          3. Recent history of hospitalization due to an exacerbation of airway disease within 3
             months or need for increased treatments for COPD within 6 weeks prior to the Screening
             Visit

          4. Primary diagnosis of asthma

          5. Prior lung volume reduction surgery or history of chest/lung irradiation

          6. Regular use of daily oxygen therapy

          7. Use of systemic (eg, intramuscular or intravenous) steroids within 3 months prior to
             the Screening Visit

          8. Respiratory tract infection within 6 weeks prior to the Screening Visit

          9. History of tuberculosis, bronchiectasis or other non- specific pulmonary disease

         10. History of urinary retention or bladder neck obstruction type symptoms

         11. History of narrow-angle glaucoma

         12. Clinically significant abnormal ECG

         13. Positive Hepatitis B surface antigen or positive Hepatitis C antibody

         14. Positive screening test for HIV antibodies

         15. Current or recent history (previous 12 months) of excessive use or abuse of alcohol

         16. Current evidence or history of abusing legal drugs or use of illegal drugs or
             substances

         17. Donation of 450 mL of blood within 8 weeks of the Screening Visit

         18. History of hypersensitivity or intolerance to aerosol medications

         19. Participation in another investigational drug study was received within 30 days prior
             to the Screening Visit
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ahmet Tutuncu, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Elevation Pharmaceuticals, Inc., (now known as Sunovion Respriatory Developement Inc.)</affiliation>
  </overall_official>
  <results_reference>
    <citation>Leaker BR, Barnes PJ, Jones CR, Tutuncu A, Singh D. Efficacy and safety of nebulized glycopyrrolate for administration using a high efficiency nebulizer in patients with chronic obstructive pulmonary disease. Br J Clin Pharmacol. 2015 Mar;79(3):492-500. doi: 10.1111/bcp.12517.</citation>
    <PMID>25243340</PMID>
  </results_reference>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 26, 2016</study_first_submitted>
  <study_first_submitted_qc>October 27, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 28, 2016</study_first_posted>
  <results_first_submitted>January 2, 2018</results_first_submitted>
  <results_first_submitted_qc>March 7, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">March 12, 2018</results_first_posted>
  <last_update_submitted>March 7, 2018</last_update_submitted>
  <last_update_submitted_qc>March 7, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 12, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Chronic Obstructive Pulmonary Disease</keyword>
  <keyword>COPD</keyword>
  <keyword>Emphysema</keyword>
  <keyword>Chronic bronchitis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
    <mesh_term>Glycopyrrolate</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>All enrolled subjects were randomized. all randomized subjects received at least one dose of study medication</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Treatment Group 1</title>
          <description>subjects received placebo, glycopyrrolate 400mcg, glycopyrrolate 50 mcg, glycopyrrolate 12.5 mcg, glycoyrrolate 200mcg, or glycopryrrolate 100mcg</description>
        </group>
        <group group_id="P2">
          <title>Treatment Group 2</title>
          <description>subjects received glycopyrrolate 12.5 mcg, glycopyrrolate 50 mcg, glycopryrrolate 100mcg, placebo, glycopyrrolate 200mcg, glycoyrrolate 400mcg, or placebo</description>
        </group>
        <group group_id="P3">
          <title>Treatment Group 3</title>
          <description>subjects received glycopyrrolate 50 mcg, Placebo, glycopyrrolate 200 mcg, glycopryrrolate 100mcg, glycopyrrolate 12.5mcg, or glycoyrrolate 400mcg</description>
        </group>
        <group group_id="P4">
          <title>Treatment Group 4</title>
          <description>subjects received glycopyrrolate 100 mcg, glycopyrrolate 200 mcg, glycopryrrolate 400mcg, placebo, glycopyrrolate 50mcg, or glycoyrrolate 12.5mcg</description>
        </group>
        <group group_id="P5">
          <title>Treatment Group 5</title>
          <description>subjects received glycopyrrolate 200 mcg, glycopyrrolate 12.5 mcg, placebo, glycopryrrolate 400mcg, placebo, glycopyrrolate 100mcg, or glycoyrrolate 50mcg</description>
        </group>
        <group group_id="P6">
          <title>Treatment Group 6</title>
          <description>subjects received glycopyrrolate 400 mcg, glycopyrrolate 100 mcg, glycopryrrolate 12.5mcg, glycopyrrolate 50mcg, placebo or glycoyrrolate 200mcg</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Treatment Period 1</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="7"/>
                <participants group_id="P4" count="7"/>
                <participants group_id="P5" count="7"/>
                <participants group_id="P6" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="7"/>
                <participants group_id="P4" count="7"/>
                <participants group_id="P5" count="7"/>
                <participants group_id="P6" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Washout Period 1</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="7"/>
                <participants group_id="P4" count="7"/>
                <participants group_id="P5" count="7"/>
                <participants group_id="P6" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="7"/>
                <participants group_id="P4" count="7"/>
                <participants group_id="P5" count="7"/>
                <participants group_id="P6" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Treatment Period 2</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="7"/>
                <participants group_id="P4" count="7"/>
                <participants group_id="P5" count="7"/>
                <participants group_id="P6" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="7"/>
                <participants group_id="P4" count="7"/>
                <participants group_id="P5" count="7"/>
                <participants group_id="P6" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Washout Period 2</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="7"/>
                <participants group_id="P4" count="7"/>
                <participants group_id="P5" count="7"/>
                <participants group_id="P6" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="7"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="7"/>
                <participants group_id="P6" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>personal reasons</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Treatment Period 3</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="7"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="7"/>
                <participants group_id="P6" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="7"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="7"/>
                <participants group_id="P6" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Washout Period 3</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="7"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="7"/>
                <participants group_id="P6" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="7"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="7"/>
                <participants group_id="P6" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Treatment Period 4</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="7"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="7"/>
                <participants group_id="P6" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="7"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="7"/>
                <participants group_id="P6" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Washout Period 4</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="7"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="7"/>
                <participants group_id="P6" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="7"/>
                <participants group_id="P6" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Treatment Period 5</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="7"/>
                <participants group_id="P6" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="7"/>
                <participants group_id="P6" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Washout Period 5</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="7"/>
                <participants group_id="P6" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="7"/>
                <participants group_id="P6" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Treatment Period 6</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="7"/>
                <participants group_id="P6" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="7"/>
                <participants group_id="P6" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Wshout Period 6</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="7"/>
                <participants group_id="P6" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="7"/>
                <participants group_id="P6" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Intent to treat population same as safety population -not full analysis set</population>
      <group_list>
        <group group_id="B1">
          <title>Total Participants</title>
          <description>Intent to treat population same as safety population -not full analysis set</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="42"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="62.0" spread="6.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="42"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="41"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United Kingdom</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Trough FEV1 (Change From Baseline)</title>
        <description>Spirometry measurements were conducted in accordance with the current ATS/ERS 2005 guidelines.
Trough FEV1 was defined as the mean of FEV1 values obtained at 23 hours 30 minutes and 24 hours post-dose of each Treatment Visit.</description>
        <time_frame>24hr post dose</time_frame>
        <population>All subjects who received at least one dose of study medication and had at least one postbaseline efficacy measurement (FEV1) were included in the intent-to-treat analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Glycopyrrolate Inhalation Solution12.5μg</title>
            <description>Glycopyrrolate Inhalation Solution12.5μg via e-flow nebulizer, once daily
Glycopyrrolate Inhalation Solution12.5μg: Glycopyrrolate Inhalation Solution12.5μg via eFlow, once daily</description>
          </group>
          <group group_id="O2">
            <title>Glycopyrrolate Inhalation Solution 50μg</title>
            <description>Glycopyrrolate Inhalation Solution 50mg via e-flow nebulizer, once daily
Glycopyrrolate Inhalation Solution 50μg: Glycopyrrolate Inhalation Solution 50μg via eFlow, once daily</description>
          </group>
          <group group_id="O3">
            <title>Glycopyrrolate Inhalation Solution 100μg</title>
            <description>Glycopyrrolate Inhalation Solution 100μg via e-flow nebulizer, once daily
Glycopyrrolate Inhalation Solution 100μg: Glycopyrrolate Inhalation Solution 100μg via eFlow, once daily</description>
          </group>
          <group group_id="O4">
            <title>Glycopyrrolate Inhalation Solution 200μg</title>
            <description>Glycopyrrolate Inhalation Solution 200μg via e-flow nebulizer, once daily
Glycopyrrolate Inhalation Solution 200μg: Glycopyrrolate Inhalation Solution 200μg via eFlow, once daily</description>
          </group>
          <group group_id="O5">
            <title>Glycopyrrolate Inhalation Solution 400μg</title>
            <description>Glycopyrrolate Inhalation Solution 400μg via e-flow nebulizer, once daily
Glycopyrrolate Inhalation Solution 400μg: Glycopyrrolate Inhalation Solution 400μg via eFlow, once daily</description>
          </group>
          <group group_id="O6">
            <title>Placebo 0.5mL</title>
            <description>Placebo 0.5mL via e-flow nebulizer, once daily
Placebo 0.5mL: Placebo 0.5mL via eFlow, once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Trough FEV1 (Change From Baseline)</title>
          <description>Spirometry measurements were conducted in accordance with the current ATS/ERS 2005 guidelines.
Trough FEV1 was defined as the mean of FEV1 values obtained at 23 hours 30 minutes and 24 hours post-dose of each Treatment Visit.</description>
          <population>All subjects who received at least one dose of study medication and had at least one postbaseline efficacy measurement (FEV1) were included in the intent-to-treat analysis.</population>
          <units>liters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
                <count group_id="O2" value="38"/>
                <count group_id="O3" value="37"/>
                <count group_id="O4" value="37"/>
                <count group_id="O5" value="37"/>
                <count group_id="O6" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.093" spread="0.1189"/>
                    <measurement group_id="O2" value="0.0114" spread="0.1308"/>
                    <measurement group_id="O3" value="0.0447" spread="0.1548"/>
                    <measurement group_id="O4" value="0.0542" spread="0.1779"/>
                    <measurement group_id="O5" value="0.0292" spread="0.1468"/>
                    <measurement group_id="O6" value="-0.0612" spread="0.1233"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>An analysis of covariance was used with change from baseline in trough FEV1 as the response, with factors for center, treatment, period, sequence, baseline FEV1 as a covariate and a random effect for subject nested within sequence.
A sample size of 34 subjects (42 with dropouts) provides 80% power to detect a 0.14L difference in mean change trough FEV1 between 2 groups at an alpha of 0.05 using a 2-tailed t-test and assuming a common standard deviation for change in trough FEV1 of 0.2.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.1257</p_value>
            <method>least squares mean</method>
            <param_type>least squares mean</param_type>
            <param_value>0.033</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.009</ci_lower_limit>
            <ci_upper_limit>0.075</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>An analysis of covariance was used with change from baseline in trough FEV1 as the response, with factors for center, treatment, period, sequence, baseline FEV1 as a covariate and a random effect for subject nested within sequence.
A sample size of 34 subjects (42 with dropouts) provides 80% power to detect a 0.14L difference in mean change trough FEV1 between 2 groups at an alpha of 0.05 using a 2-tailed t-test and assuming a common standard deviation for change in trough FEV1 of 0.2.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0008</p_value>
            <method>least squares mean</method>
            <param_type>least squares mean</param_type>
            <param_value>0.072</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.030</ci_lower_limit>
            <ci_upper_limit>0.113</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>An analysis of covariance was used with change from baseline in trough FEV1 as the response, with factors for center, treatment, period, sequence, baseline FEV1 as a covariate and a random effect for subject nested within sequence.
A sample size of 34 subjects (42 with dropouts) provides 80% power to detect a 0.14L difference in mean change trough FEV1 between 2 groups at an alpha of 0.05 using a 2-tailed t-test and assuming a common standard deviation for change in trough FEV1 of 0.2.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>least squares mean</method>
            <param_type>least squares mean</param_type>
            <param_value>0.102</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.061</ci_lower_limit>
            <ci_upper_limit>0.144</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>An analysis of covariance was used with change from baseline in trough FEV1 as the response, with factors for center, treatment, period, sequence, baseline FEV1 as a covariate and a random effect for subject nested within sequence.
A sample size of 34 subjects (42 with dropouts) provides 80% power to detect a 0.14L difference in mean change trough FEV1 between 2 groups at an alpha of 0.05 using a 2-tailed t-test and assuming a common standard deviation for change in trough FEV1 of 0.2.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>least squares mean</method>
            <param_type>least squares mean</param_type>
            <param_value>0.108</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.066</ci_lower_limit>
            <ci_upper_limit>0.150</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>An analysis of covariance was used with change from baseline in trough FEV1 as the response, with factors for center, treatment, period, sequence, baseline FEV1 as a covariate and a random effect for subject nested within sequence.
A sample size of 34 subjects (42 with dropouts) provides 80% power to detect a 0.14L difference in mean change trough FEV1 between 2 groups at an alpha of 0.05 using a 2-tailed t-test and assuming a common standard deviation for change in trough FEV1 of 0.2.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>least squares mean</method>
            <param_type>least squares mean</param_type>
            <param_value>0.098</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.056</ci_lower_limit>
            <ci_upper_limit>0.140</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Standardized FEV1AUC0-12 Area Under the FEV1 Curve From 0 to 12 Hours Post-dose ( Actual and Change From Baseline).</title>
        <description>Spirometry measurements were conducted in accordance with the current ATS/ERS 2005 guidelines.. The standardized actual FEV1 AUC(0-12) was calculated using the trapezoidal rule divided by the actual hours from the first FEV1 to the last FEV1 in the interval. Standardized change from baseline FEV1 AUC(0-12) was also calculated similarly, using the change from pre-dose FEV1.</description>
        <time_frame>0-12h post dose</time_frame>
        <population>All subjects who received at least one dose of study medication and had at least one postbaseline efficacy measurement (FEV1) were included in the intent to treat analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Glycopyrrolate Inhalation Solution12.5μg</title>
            <description>Glycopyrrolate Inhalation Solution12.5μg via e-flow nebulizer, once daily
Glycopyrrolate Inhalation Solution12.5μg: Glycopyrrolate Inhalation Solution12.5μg via eFlow, once daily</description>
          </group>
          <group group_id="O2">
            <title>Glycopyrrolate Inhalation Solution 50μg</title>
            <description>Glycopyrrolate Inhalation Solution 50mg via e-flow nebulizer, once daily
Glycopyrrolate Inhalation Solution 50μg: Glycopyrrolate Inhalation Solution 50μg via eFlow, once daily</description>
          </group>
          <group group_id="O3">
            <title>Glycopyrrolate Inhalation Solution 100μg</title>
            <description>Glycopyrrolate Inhalation Solution 100μg via e-flow nebulizer, once daily
Glycopyrrolate Inhalation Solution 100μg: Glycopyrrolate Inhalation Solution 100μg via eFlow, once daily</description>
          </group>
          <group group_id="O4">
            <title>Glycopyrrolate Inhalation Solution 200μg</title>
            <description>Glycopyrrolate Inhalation Solution 200μg via e-flow nebulizer, once daily
Glycopyrrolate Inhalation Solution 200μg: Glycopyrrolate Inhalation Solution 200μg via eFlow, once daily</description>
          </group>
          <group group_id="O5">
            <title>Glycopyrrolate Inhalation Solution 400μg</title>
            <description>Glycopyrrolate Inhalation Solution 400μg via e-flow nebulizer, once daily
Glycopyrrolate Inhalation Solution 400μg: Glycopyrrolate Inhalation Solution 400μg via eFlow, once daily</description>
          </group>
          <group group_id="O6">
            <title>Placebo 0.5mL</title>
            <description>Placebo 0.5mL via e-flow nebulizer, once daily
Placebo 0.5mL: Placebo 0.5mL via eFlow, once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Standardized FEV1AUC0-12 Area Under the FEV1 Curve From 0 to 12 Hours Post-dose ( Actual and Change From Baseline).</title>
          <description>Spirometry measurements were conducted in accordance with the current ATS/ERS 2005 guidelines.. The standardized actual FEV1 AUC(0-12) was calculated using the trapezoidal rule divided by the actual hours from the first FEV1 to the last FEV1 in the interval. Standardized change from baseline FEV1 AUC(0-12) was also calculated similarly, using the change from pre-dose FEV1.</description>
          <population>All subjects who received at least one dose of study medication and had at least one postbaseline efficacy measurement (FEV1) were included in the intent to treat analysis</population>
          <units>liters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
                <count group_id="O2" value="38"/>
                <count group_id="O3" value="37"/>
                <count group_id="O4" value="37"/>
                <count group_id="O5" value="37"/>
                <count group_id="O6" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>actual standardized FEV1 AUC0_12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.259" spread="0.409"/>
                    <measurement group_id="O2" value="1.311" spread="0.422"/>
                    <measurement group_id="O3" value="1.335" spread="0.394"/>
                    <measurement group_id="O4" value="1.374" spread="0.391"/>
                    <measurement group_id="O5" value="1.390" spread="0.423"/>
                    <measurement group_id="O6" value="1.180" spread="0.427"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>change from baseline standardized FEV1 AUC0_12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.055" spread="0.113"/>
                    <measurement group_id="O2" value="0.126" spread="0.112"/>
                    <measurement group_id="O3" value="0.136" spread="0.134"/>
                    <measurement group_id="O4" value="0.184" spread="0.134"/>
                    <measurement group_id="O5" value="0.170" spread="0.110"/>
                    <measurement group_id="O6" value="-0.024" spread="0.095"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>An analysis of covariance was used with change from baseline in standardized FEV1 AUC0_12 as the response, with factors for center, treatment, period, sequence, baseline FEV1 as a covariate and a random effect for subject nested within sequence.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>least squares mean</method>
            <param_type>least squares mean</param_type>
            <param_value>0.086</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.050</ci_lower_limit>
            <ci_upper_limit>0.123</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>An analysis of covariance was used with change from baseline in standardized FEV1 AUC0_12 as the response, with factors for center, treatment, period, sequence, baseline FEV1 as a covariate and a random effect for subject nested within sequence.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>least squares mean</method>
            <param_type>least squares mean</param_type>
            <param_value>0.151</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.114</ci_lower_limit>
            <ci_upper_limit>0.187</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>An analysis of covariance was used with change from baseline in standardized FEV1 AUC0_12 as the response, with factors for center, treatment, period, sequence, baseline FEV1 as a covariate and a random effect for subject nested within sequence.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>least squares mean</method>
            <param_type>least squares mean</param_type>
            <param_value>0.156</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.120</ci_lower_limit>
            <ci_upper_limit>0.193</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>An analysis of covariance was used with change from baseline in standardized FEV1 AUC0_12 as the response, with factors for center, treatment, period, sequence, baseline FEV1 as a covariate and a random effect for subject nested within sequence.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>least squares mean</method>
            <param_type>least squares mean</param_type>
            <param_value>0.202</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.165</ci_lower_limit>
            <ci_upper_limit>0.239</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>An analysis of covariance was used with change from baseline in standardized FEV1 AUC0_12 as the response, with factors for center, treatment, period, sequence, baseline FEV1 as a covariate and a random effect for subject nested within sequence.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>least squares mean</method>
            <param_type>least squares mean</param_type>
            <param_value>0.199</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.162</ci_lower_limit>
            <ci_upper_limit>0.235</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Standardized FEV1AUC12-24 Area Under the FEV1 Curve From 12 to 24 Hours Post- Dose (Actual and Change From Baseline).</title>
        <description>Spirometry measurements were conducted in accordance with the current ATS/ERS 2005 guidelines. The standardized actual FEV1 AUC(12-24) was calculated using the trapezoidal rule divided by the actual hours from the first FEV1 to the last FEV1 in the interval. Standardized change from baseline FEV1 AUC(12-24) was also calculated similarly, using the change from pre-dose FEV1.</description>
        <time_frame>12-24h post dose</time_frame>
        <population>All subjects who received at least one dose of study medication and had at least one postbaseline efficacy measurement (FEV1) were included in the intent to treat analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Glycopyrrolate Inhalation Solution12.5μg</title>
            <description>Glycopyrrolate Inhalation Solution12.5μg via e-flow nebulizer, once daily
Glycopyrrolate Inhalation Solution12.5μg: Glycopyrrolate Inhalation Solution12.5μg via eFlow, once daily</description>
          </group>
          <group group_id="O2">
            <title>Glycopyrrolate Inhalation Solution 50μg</title>
            <description>Glycopyrrolate Inhalation Solution 50mg via e-flow nebulizer, once daily
Glycopyrrolate Inhalation Solution 50μg: Glycopyrrolate Inhalation Solution 50μg via eFlow, once daily</description>
          </group>
          <group group_id="O3">
            <title>Glycopyrrolate Inhalation Solution 100μg</title>
            <description>Glycopyrrolate Inhalation Solution 100μg via e-flow nebulizer, once daily
Glycopyrrolate Inhalation Solution 100μg: Glycopyrrolate Inhalation Solution 100μg via eFlow, once daily</description>
          </group>
          <group group_id="O4">
            <title>Glycopyrrolate Inhalation Solution 200μg</title>
            <description>Glycopyrrolate Inhalation Solution 200μg via e-flow nebulizer, once daily
Glycopyrrolate Inhalation Solution 200μg: Glycopyrrolate Inhalation Solution 200μg via eFlow, once daily</description>
          </group>
          <group group_id="O5">
            <title>Glycopyrrolate Inhalation Solution 400μg</title>
            <description>Glycopyrrolate Inhalation Solution 400μg via e-flow nebulizer, once daily
Glycopyrrolate Inhalation Solution 400μg: Glycopyrrolate Inhalation Solution 400μg via eFlow, once daily</description>
          </group>
          <group group_id="O6">
            <title>Placebo 0.5mL</title>
            <description>Placebo 0.5mL via e-flow nebulizer, once daily
Placebo 0.5mL: Placebo 0.5mL via eFlow, once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Standardized FEV1AUC12-24 Area Under the FEV1 Curve From 12 to 24 Hours Post- Dose (Actual and Change From Baseline).</title>
          <description>Spirometry measurements were conducted in accordance with the current ATS/ERS 2005 guidelines. The standardized actual FEV1 AUC(12-24) was calculated using the trapezoidal rule divided by the actual hours from the first FEV1 to the last FEV1 in the interval. Standardized change from baseline FEV1 AUC(12-24) was also calculated similarly, using the change from pre-dose FEV1.</description>
          <population>All subjects who received at least one dose of study medication and had at least one postbaseline efficacy measurement (FEV1) were included in the intent to treat analysis</population>
          <units>liters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
                <count group_id="O2" value="38"/>
                <count group_id="O3" value="37"/>
                <count group_id="O4" value="37"/>
                <count group_id="O5" value="37"/>
                <count group_id="O6" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>acutal standardized FEV1 AUC0_12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.165" spread="0.377"/>
                    <measurement group_id="O2" value="1.203" spread="0.404"/>
                    <measurement group_id="O3" value="1.227" spread="0.369"/>
                    <measurement group_id="O4" value="1.253" spread="0.346"/>
                    <measurement group_id="O5" value="1.259" spread="0.396"/>
                    <measurement group_id="O6" value="1.123" spread="0.392"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>change from baseline standardized FEV1 AUC0_12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.038" spread="0.132"/>
                    <measurement group_id="O2" value="0.018" spread="0.135"/>
                    <measurement group_id="O3" value="0.028" spread="0.138"/>
                    <measurement group_id="O4" value="0.063" spread="0.178"/>
                    <measurement group_id="O5" value="0.039" spread="0.135"/>
                    <measurement group_id="O6" value="-0.082" spread="0.120"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>An analysis of covariance was used with change from baseline in standardized FEV1 AUC12_24 as the response, with factors for center, treatment, period, sequence, baseline FEV1 as a covariate and a random effect for subject nested within sequence.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0028</p_value>
            <method>least squares mean</method>
            <param_type>least squares mean</param_type>
            <param_value>0.058</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.021</ci_lower_limit>
            <ci_upper_limit>0.095</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>An analysis of covariance was used with change from baseline in standardized FEV1 AUC12_24 as the response, with factors for center, treatment, period, sequence, baseline FEV1 as a covariate and a random effect for subject nested within sequence.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>least squares mena</method>
            <param_type>least squares mean</param_type>
            <param_value>0.100</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.063</ci_lower_limit>
            <ci_upper_limit>0.137</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>An analysis of covariance was used with change from baseline in standardized FEV1 AUC12_24 as the response, with factors for center, treatment, period, sequence, baseline FEV1 as a covariate and a random effect for subject nested within sequence.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>least squares mean</method>
            <param_type>least squares mean</param_type>
            <param_value>0.105</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.068</ci_lower_limit>
            <ci_upper_limit>0.142</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>An analysis of covariance was used with change from baseline in standardized FEV1 AUC12_24 as the response, with factors for center, treatment, period, sequence, baseline FEV1 as a covariate and a random effect for subject nested within sequence.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>least squares mean</method>
            <param_type>least squares mean</param_type>
            <param_value>0.135</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.098</ci_lower_limit>
            <ci_upper_limit>0.173</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>An analysis of covariance was used with change from baseline in standardized FEV1 AUC12_24 as the response, with factors for center, treatment, period, sequence, baseline FEV1 as a covariate and a random effect for subject nested within sequence.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>least squares mean</method>
            <param_type>least squares mean</param_type>
            <param_value>0.128</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.091</ci_lower_limit>
            <ci_upper_limit>0.166</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Standardized FEV1 AUC0-24 Area Under the FEV1 Curve From 0 to 24 Hours Post-dose (Actual and Change Baseline)</title>
        <description>Spirometry measurements were conducted in accordance with the current ATS/ERS 2005 guidelines. . The standardized actual FEV1 AUC(0-24) was calculated using the trapezoidal rule divided by the actual hours from the first FEV1 to the last FEV1 in the interval. Standardized change from baseline FEV1 AUC(0-24) was also calculated similarly, using the change from pre-dose FEV1.</description>
        <time_frame>0 to 24h</time_frame>
        <population>all subjects who received at least one dose of study medication and had at least one postbaseline efficacy measurement (FEV1) were included in the intent to treat analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Glycopyrrolate Inhalation Solution12.5μg</title>
            <description>Glycopyrrolate Inhalation Solution12.5μg via e-flow nebulizer, once daily
Glycopyrrolate Inhalation Solution12.5μg: Glycopyrrolate Inhalation Solution12.5μg via eFlow, once daily</description>
          </group>
          <group group_id="O2">
            <title>Glycopyrrolate Inhalation Solution 50μg</title>
            <description>Glycopyrrolate Inhalation Solution 50mg via e-flow nebulizer, once daily
Glycopyrrolate Inhalation Solution 50μg: Glycopyrrolate Inhalation Solution 50μg via eFlow, once daily</description>
          </group>
          <group group_id="O3">
            <title>Glycopyrrolate Inhalation Solution 100μg</title>
            <description>Glycopyrrolate Inhalation Solution 100μg via e-flow nebulizer, once daily
Glycopyrrolate Inhalation Solution 100μg: Glycopyrrolate Inhalation Solution 100μg via eFlow, once daily</description>
          </group>
          <group group_id="O4">
            <title>Glycopyrrolate Inhalation Solution 200μg</title>
            <description>Glycopyrrolate Inhalation Solution 200μg via e-flow nebulizer, once daily
Glycopyrrolate Inhalation Solution 200μg: Glycopyrrolate Inhalation Solution 200μg via eFlow, once daily</description>
          </group>
          <group group_id="O5">
            <title>Glycopyrrolate Inhalation Solution 400μg</title>
            <description>Glycopyrrolate Inhalation Solution 400μg via e-flow nebulizer, once daily
Glycopyrrolate Inhalation Solution 400μg: Glycopyrrolate Inhalation Solution 400μg via eFlow, once daily</description>
          </group>
          <group group_id="O6">
            <title>Placebo 0.5mL</title>
            <description>Placebo 0.5mL via e-flow nebulizer, once daily
Placebo 0.5mL: Placebo 0.5mL via eFlow, once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Standardized FEV1 AUC0-24 Area Under the FEV1 Curve From 0 to 24 Hours Post-dose (Actual and Change Baseline)</title>
          <description>Spirometry measurements were conducted in accordance with the current ATS/ERS 2005 guidelines. . The standardized actual FEV1 AUC(0-24) was calculated using the trapezoidal rule divided by the actual hours from the first FEV1 to the last FEV1 in the interval. Standardized change from baseline FEV1 AUC(0-24) was also calculated similarly, using the change from pre-dose FEV1.</description>
          <population>all subjects who received at least one dose of study medication and had at least one postbaseline efficacy measurement (FEV1) were included in the intent to treat analysis</population>
          <units>liters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
                <count group_id="O2" value="38"/>
                <count group_id="O3" value="37"/>
                <count group_id="O4" value="37"/>
                <count group_id="O5" value="37"/>
                <count group_id="O6" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Actual standardized FEV1 AUC0_12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.212" spread="0.391"/>
                    <measurement group_id="O2" value="1.257" spread="0.411"/>
                    <measurement group_id="O3" value="1.281" spread="0.379"/>
                    <measurement group_id="O4" value="1.313" spread="0.364"/>
                    <measurement group_id="O5" value="1.325" spread="0.407"/>
                    <measurement group_id="O6" value="1.151" spread="0.408"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>change from baseline standardized FEV1 AUC0_12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.009" spread="0.114"/>
                    <measurement group_id="O2" value="0.072" spread="0.115"/>
                    <measurement group_id="O3" value="0.082" spread="0.128"/>
                    <measurement group_id="O4" value="0.123" spread="0.146"/>
                    <measurement group_id="O5" value="0.105" spread="0.113"/>
                    <measurement group_id="O6" value="-0.053" spread="0.102"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Peak FEV1 (Change From Baseline and Percent Change)</title>
        <description>spirometry measurements were conducted in accordance with the current ATS/ERS 2005 guidelines. . The peak FEV1 was defined as the highest post-dose FEV1 value within 4 hrs after the dose. Percent change from baseline was calculated as 100 times the difference of peak FEV1 minus baseline FEV1 divided by baseline FEV1.</description>
        <time_frame>0-4h post dose</time_frame>
        <population>all subjects who received at least one dose of study medication and have at least one post baseline efficacy measurement were included in the efficacy population</population>
        <group_list>
          <group group_id="O1">
            <title>Glycopyrrolate Inhalation Solution12.5μg</title>
            <description>Glycopyrrolate Inhalation Solution12.5μg via e-flow nebulizer, once daily
Glycopyrrolate Inhalation Solution12.5μg: Glycopyrrolate Inhalation Solution12.5μg via eFlow, once daily</description>
          </group>
          <group group_id="O2">
            <title>Glycopyrrolate Inhalation Solution 50μg</title>
            <description>Glycopyrrolate Inhalation Solution 50mg via e-flow nebulizer, once daily
Glycopyrrolate Inhalation Solution 50μg: Glycopyrrolate Inhalation Solution 50μg via eFlow, once daily</description>
          </group>
          <group group_id="O3">
            <title>Glycopyrrolate Inhalation Solution 100μg</title>
            <description>Glycopyrrolate Inhalation Solution 100μg via e-flow nebulizer, once daily
Glycopyrrolate Inhalation Solution 100μg: Glycopyrrolate Inhalation Solution 100μg via eFlow, once daily</description>
          </group>
          <group group_id="O4">
            <title>Glycopyrrolate Inhalation Solution 200μg</title>
            <description>Glycopyrrolate Inhalation Solution 200μg via e-flow nebulizer, once daily
Glycopyrrolate Inhalation Solution 200μg: Glycopyrrolate Inhalation Solution 200μg via eFlow, once daily</description>
          </group>
          <group group_id="O5">
            <title>Glycopyrrolate Inhalation Solution 400μg</title>
            <description>Glycopyrrolate Inhalation Solution 400μg via e-flow nebulizer, once daily
Glycopyrrolate Inhalation Solution 400μg: Glycopyrrolate Inhalation Solution 400μg via eFlow, once daily</description>
          </group>
          <group group_id="O6">
            <title>Placebo 0.5mL</title>
            <description>Placebo 0.5mL via e-flow nebulizer, once daily
Placebo 0.5mL: Placebo 0.5mL via eFlow, once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Peak FEV1 (Change From Baseline and Percent Change)</title>
          <description>spirometry measurements were conducted in accordance with the current ATS/ERS 2005 guidelines. . The peak FEV1 was defined as the highest post-dose FEV1 value within 4 hrs after the dose. Percent change from baseline was calculated as 100 times the difference of peak FEV1 minus baseline FEV1 divided by baseline FEV1.</description>
          <population>all subjects who received at least one dose of study medication and have at least one post baseline efficacy measurement were included in the efficacy population</population>
          <units>liters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
                <count group_id="O2" value="38"/>
                <count group_id="O3" value="37"/>
                <count group_id="O4" value="37"/>
                <count group_id="O5" value="37"/>
                <count group_id="O6" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change from baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.165" spread="0.113"/>
                    <measurement group_id="O2" value="0.229" spread="0.113"/>
                    <measurement group_id="O3" value="0.260" spread="0.151"/>
                    <measurement group_id="O4" value="0.292" spread="0.120"/>
                    <measurement group_id="O5" value="0.272" spread="0.125"/>
                    <measurement group_id="O6" value="0.061" spread="0.102"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>percent change from baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.30" spread="11.37"/>
                    <measurement group_id="O2" value="21.05" spread="11.87"/>
                    <measurement group_id="O3" value="24.14" spread="20.69"/>
                    <measurement group_id="O4" value="26.73" spread="12.56"/>
                    <measurement group_id="O5" value="25.44" spread="15.10"/>
                    <measurement group_id="O6" value="5.24" spread="8275"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cmax; Maximum Observed Plasma Concentration</title>
        <description>Pk parameters are calculated from glycopyrrolate plasma concentration analysed from serial blood samples collected between 0 and 12 hr</description>
        <time_frame>0 to 12 hour</time_frame>
        <population>All subjects who received at least one dose of EP-101 and who have sufficient blood samples taken to obtain a plasma concentration by time profile and have no major protocol violations were included in the PK analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Glycopyrrolate Inhalation Solution12.5μg</title>
            <description>Glycopyrrolate Inhalation Solution12.5μg via e-flow nebulizer, once daily
Glycopyrrolate Inhalation Solution12.5μg: Glycopyrrolate Inhalation Solution12.5μg via eFlow, once daily</description>
          </group>
          <group group_id="O2">
            <title>Glycopyrrolate Inhalation Solution 50μg</title>
            <description>Glycopyrrolate Inhalation Solution 50mg via e-flow nebulizer, once daily
Glycopyrrolate Inhalation Solution 50μg: Glycopyrrolate Inhalation Solution 50μg via eFlow, once daily</description>
          </group>
          <group group_id="O3">
            <title>Glycopyrrolate Inhalation Solution 100μg</title>
            <description>Glycopyrrolate Inhalation Solution 100μg via e-flow nebulizer, once daily
Glycopyrrolate Inhalation Solution 100μg: Glycopyrrolate Inhalation Solution 100μg via eFlow, once daily</description>
          </group>
          <group group_id="O4">
            <title>Glycopyrrolate Inhalation Solution 200μg</title>
            <description>Glycopyrrolate Inhalation Solution 200μg via e-flow nebulizer, once daily
Glycopyrrolate Inhalation Solution 200μg: Glycopyrrolate Inhalation Solution 200μg via eFlow, once daily</description>
          </group>
          <group group_id="O5">
            <title>Glycopyrrolate Inhalation Solution 400μg</title>
            <description>Glycopyrrolate Inhalation Solution 400μg via e-flow nebulizer, once daily
Glycopyrrolate Inhalation Solution 400μg: Glycopyrrolate Inhalation Solution 400μg via eFlow, once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax; Maximum Observed Plasma Concentration</title>
          <description>Pk parameters are calculated from glycopyrrolate plasma concentration analysed from serial blood samples collected between 0 and 12 hr</description>
          <population>All subjects who received at least one dose of EP-101 and who have sufficient blood samples taken to obtain a plasma concentration by time profile and have no major protocol violations were included in the PK analysis.</population>
          <units>pg/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="13"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="12"/>
                <count group_id="O5" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59.25" spread="78.49"/>
                    <measurement group_id="O2" value="74.48" spread="62.24"/>
                    <measurement group_id="O3" value="144.58" spread="52.53"/>
                    <measurement group_id="O4" value="316.05" spread="48.35"/>
                    <measurement group_id="O5" value="504.93" spread="55.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Tmax; Time to Maximum Observed Plasma Concentration</title>
        <description>Pk parameters are calculated from glycopyrrolate plasma concentration analysed from serial blood samples collected between 0 and 12 hr</description>
        <time_frame>0 to 12 hours</time_frame>
        <population>All subjects who received at least one dose of EP-101 and who have sufficient blood samples taken to obtain a plasma concentration by time profile and have no major protocol violations were included in the PK analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Glycopyrrolate Inhalation Solution12.5μg</title>
            <description>Glycopyrrolate Inhalation Solution12.5μg via e-flow nebulizer, once daily
Glycopyrrolate Inhalation Solution12.5μg: Glycopyrrolate Inhalation Solution12.5μg via eFlow, once daily</description>
          </group>
          <group group_id="O2">
            <title>Glycopyrrolate Inhalation Solution 50μg</title>
            <description>Glycopyrrolate Inhalation Solution 50mg via e-flow nebulizer, once daily
Glycopyrrolate Inhalation Solution 50μg: Glycopyrrolate Inhalation Solution 50μg via eFlow, once daily</description>
          </group>
          <group group_id="O3">
            <title>Glycopyrrolate Inhalation Solution 100μg</title>
            <description>Glycopyrrolate Inhalation Solution 100μg via e-flow nebulizer, once daily
Glycopyrrolate Inhalation Solution 100μg: Glycopyrrolate Inhalation Solution 100μg via eFlow, once daily</description>
          </group>
          <group group_id="O4">
            <title>Glycopyrrolate Inhalation Solution 200μg</title>
            <description>Glycopyrrolate Inhalation Solution 200μg via e-flow nebulizer, once daily
Glycopyrrolate Inhalation Solution 200μg: Glycopyrrolate Inhalation Solution 200μg via eFlow, once daily</description>
          </group>
          <group group_id="O5">
            <title>Glycopyrrolate Inhalation Solution 400μg</title>
            <description>Glycopyrrolate Inhalation Solution 400μg via e-flow nebulizer, once daily
Glycopyrrolate Inhalation Solution 400μg: Glycopyrrolate Inhalation Solution 400μg via eFlow, once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Tmax; Time to Maximum Observed Plasma Concentration</title>
          <description>Pk parameters are calculated from glycopyrrolate plasma concentration analysed from serial blood samples collected between 0 and 12 hr</description>
          <population>All subjects who received at least one dose of EP-101 and who have sufficient blood samples taken to obtain a plasma concentration by time profile and have no major protocol violations were included in the PK analysis.</population>
          <units>hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="13"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="12"/>
                <count group_id="O5" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.165" lower_limit="0.150" upper_limit="0.180"/>
                    <measurement group_id="O2" value="0.320" lower_limit=".0150" upper_limit="0.350"/>
                    <measurement group_id="O3" value="0.260" lower_limit="0.150" upper_limit="0.330"/>
                    <measurement group_id="O4" value="0.275" lower_limit="0.150" upper_limit="0.380"/>
                    <measurement group_id="O5" value="0.180" lower_limit="0.150" upper_limit="0.320"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>t1/2; Plasma Half-life</title>
        <description>Pk parameters are calculated from glycopyrrolate plasma concentration analysed from serial blood samples collected between 0 and 12 hr</description>
        <time_frame>0 to 12 hour</time_frame>
        <population>All subjects who received at least one dose of EP-101 and who have sufficient blood samples taken to obtain a plasma concentration by time profile and have no major protocol violations were included in the PK analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Glycopyrrolate Inhalation Solution12.5μg</title>
            <description>Glycopyrrolate Inhalation Solution12.5μg via e-flow nebulizer, once daily
Glycopyrrolate Inhalation Solution12.5μg: Glycopyrrolate Inhalation Solution12.5μg via eFlow, once daily</description>
          </group>
          <group group_id="O2">
            <title>Glycopyrrolate Inhalation Solution 50μg</title>
            <description>Glycopyrrolate Inhalation Solution 50mg via e-flow nebulizer, once daily
Glycopyrrolate Inhalation Solution 50μg: Glycopyrrolate Inhalation Solution 50μg via eFlow, once daily</description>
          </group>
          <group group_id="O3">
            <title>Glycopyrrolate Inhalation Solution 100μg</title>
            <description>Glycopyrrolate Inhalation Solution 100μg via e-flow nebulizer, once daily
Glycopyrrolate Inhalation Solution 100μg: Glycopyrrolate Inhalation Solution 100μg via eFlow, once daily</description>
          </group>
          <group group_id="O4">
            <title>Glycopyrrolate Inhalation Solution 200μg</title>
            <description>Glycopyrrolate Inhalation Solution 200μg via e-flow nebulizer, once daily
Glycopyrrolate Inhalation Solution 200μg: Glycopyrrolate Inhalation Solution 200μg via eFlow, once daily</description>
          </group>
          <group group_id="O5">
            <title>Glycopyrrolate Inhalation Solution 400μg</title>
            <description>Glycopyrrolate Inhalation Solution 400μg via e-flow nebulizer, once daily
Glycopyrrolate Inhalation Solution 400μg: Glycopyrrolate Inhalation Solution 400μg via eFlow, once daily</description>
          </group>
        </group_list>
        <measure>
          <title>t1/2; Plasma Half-life</title>
          <description>Pk parameters are calculated from glycopyrrolate plasma concentration analysed from serial blood samples collected between 0 and 12 hr</description>
          <population>All subjects who received at least one dose of EP-101 and who have sufficient blood samples taken to obtain a plasma concentration by time profile and have no major protocol violations were included in the PK analysis.</population>
          <units>hours</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="2"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="7"/>
                <count group_id="O5" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="0.8949" spread="2.3707"/>
                    <measurement group_id="O3" value="3.0137" spread="50.7557"/>
                    <measurement group_id="O4" value="3.1663" spread="45.4839"/>
                    <measurement group_id="O5" value="4.1238" spread="63.5353"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AUC0-t; Area Under the Plasma Concentration-time Curve From Time Zero to Time of Last Measurable Drug Concentration.</title>
        <description>Pk parameters are calculated from glycopyrrolate plasma concentration analysed from serial blood samples collected between 0 and 12 hr</description>
        <time_frame>0 to 12 hour</time_frame>
        <population>All subjects who received at least one dose of EP-101 and who have sufficient blood samples taken to obtain a plasma concentration by time profile and have no major protocol violations were included in the PK analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Glycopyrrolate Inhalation Solution12.5μg</title>
            <description>Glycopyrrolate Inhalation Solution12.5μg via e-flow nebulizer, once daily
Glycopyrrolate Inhalation Solution12.5μg: Glycopyrrolate Inhalation Solution12.5μg via eFlow, once daily</description>
          </group>
          <group group_id="O2">
            <title>Glycopyrrolate Inhalation Solution 50μg</title>
            <description>Glycopyrrolate Inhalation Solution 50mg via e-flow nebulizer, once daily
Glycopyrrolate Inhalation Solution 50μg: Glycopyrrolate Inhalation Solution 50μg via eFlow, once daily</description>
          </group>
          <group group_id="O3">
            <title>Glycopyrrolate Inhalation Solution 100μg</title>
            <description>Glycopyrrolate Inhalation Solution 100μg via e-flow nebulizer, once daily
Glycopyrrolate Inhalation Solution 100μg: Glycopyrrolate Inhalation Solution 100μg via eFlow, once daily</description>
          </group>
          <group group_id="O4">
            <title>Glycopyrrolate Inhalation Solution 200μg</title>
            <description>Glycopyrrolate Inhalation Solution 200μg via e-flow nebulizer, once daily
Glycopyrrolate Inhalation Solution 200μg: Glycopyrrolate Inhalation Solution 200μg via eFlow, once daily</description>
          </group>
          <group group_id="O5">
            <title>Glycopyrrolate Inhalation Solution 400μg</title>
            <description>Glycopyrrolate Inhalation Solution 400μg via e-flow nebulizer, once daily
Glycopyrrolate Inhalation Solution 400μg: Glycopyrrolate Inhalation Solution 400μg via eFlow, once daily</description>
          </group>
        </group_list>
        <measure>
          <title>AUC0-t; Area Under the Plasma Concentration-time Curve From Time Zero to Time of Last Measurable Drug Concentration.</title>
          <description>Pk parameters are calculated from glycopyrrolate plasma concentration analysed from serial blood samples collected between 0 and 12 hr</description>
          <population>All subjects who received at least one dose of EP-101 and who have sufficient blood samples taken to obtain a plasma concentration by time profile and have no major protocol violations were included in the PK analysis.</population>
          <units>pg.h/ml</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="13"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="12"/>
                <count group_id="O5" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="135.87" spread="209.27"/>
                    <measurement group_id="O2" value="67.18" spread="143.22"/>
                    <measurement group_id="O3" value="237.80" spread="98.45"/>
                    <measurement group_id="O4" value="677.24" spread="66.34"/>
                    <measurement group_id="O5" value="1481.36" spread="82.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AUC0-inf Area Under the Plasma Concentration-time Curve From Time Zero to Infinity</title>
        <description>Pk parameters are calculated from glycopyrrolate plasma concentration analysed from serial blood samples collected between 0 and 12 hr</description>
        <time_frame>0 to 12 hour</time_frame>
        <population>All subjects who received at least one dose of EP-101 and who have sufficient blood samples taken to obtain a plasma concentration by time profile and have no major protocol violations were included in the PK analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Glycopyrrolate Inhalation Solution12.5μg</title>
            <description>Glycopyrrolate Inhalation Solution12.5μg via e-flow nebulizer, once daily
Glycopyrrolate Inhalation Solution12.5μg: Glycopyrrolate Inhalation Solution12.5μg via eFlow, once daily</description>
          </group>
          <group group_id="O2">
            <title>Glycopyrrolate Inhalation Solution 50μg</title>
            <description>Glycopyrrolate Inhalation Solution 50mg via e-flow nebulizer, once daily
Glycopyrrolate Inhalation Solution 50μg: Glycopyrrolate Inhalation Solution 50μg via eFlow, once daily</description>
          </group>
          <group group_id="O3">
            <title>Glycopyrrolate Inhalation Solution 100μg</title>
            <description>Glycopyrrolate Inhalation Solution 100μg via e-flow nebulizer, once daily
Glycopyrrolate Inhalation Solution 100μg: Glycopyrrolate Inhalation Solution 100μg via eFlow, once daily</description>
          </group>
          <group group_id="O4">
            <title>Glycopyrrolate Inhalation Solution 200μg</title>
            <description>Glycopyrrolate Inhalation Solution 200μg via e-flow nebulizer, once daily
Glycopyrrolate Inhalation Solution 200μg: Glycopyrrolate Inhalation Solution 200μg via eFlow, once daily</description>
          </group>
          <group group_id="O5">
            <title>Glycopyrrolate Inhalation Solution 400μg</title>
            <description>Glycopyrrolate Inhalation Solution 400μg via e-flow nebulizer, once daily
Glycopyrrolate Inhalation Solution 400μg: Glycopyrrolate Inhalation Solution 400μg via eFlow, once daily</description>
          </group>
        </group_list>
        <measure>
          <title>AUC0-inf Area Under the Plasma Concentration-time Curve From Time Zero to Infinity</title>
          <description>Pk parameters are calculated from glycopyrrolate plasma concentration analysed from serial blood samples collected between 0 and 12 hr</description>
          <population>All subjects who received at least one dose of EP-101 and who have sufficient blood samples taken to obtain a plasma concentration by time profile and have no major protocol violations were included in the PK analysis.</population>
          <units>pg.h/ml</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="2"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="7"/>
                <count group_id="O5" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="246.84" spread="37.49"/>
                    <measurement group_id="O3" value="634.65" spread="34.28"/>
                    <measurement group_id="O4" value="772.59" spread="26.30"/>
                    <measurement group_id="O5" value="1367.76" spread="76.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Who Died, Number of Subjects With Treatment Emergent SAEs, Number of Subjects Who Discontinued Due to AE</title>
        <description>AE's are defined as existing conditions which worsen or events which occur during the course of the clinical trial after treatment</description>
        <time_frame>Day 69 (includes dosing Day 1, washout Day 12, safety follow up Day 69)</time_frame>
        <population>all subjects who received at least one dose of study drug were included in the safety analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Glycopyrrolate Inhalation Solution12.5μg</title>
            <description>Glycopyrrolate Inhalation Solution12.5μg via e-flow nebulizer, once daily
Glycopyrrolate Inhalation Solution12.5μg: Glycopyrrolate Inhalation Solution12.5μg via eFlow, once daily</description>
          </group>
          <group group_id="O2">
            <title>Glycopyrrolate Inhalation Solution 50μg</title>
            <description>Glycopyrrolate Inhalation Solution 50mg via e-flow nebulizer, once daily
Glycopyrrolate Inhalation Solution 50μg: Glycopyrrolate Inhalation Solution 50μg via eFlow, once daily</description>
          </group>
          <group group_id="O3">
            <title>Glycopyrrolate Inhalation Solution 100μg</title>
            <description>Glycopyrrolate Inhalation Solution 100μg via e-flow nebulizer, once daily
Glycopyrrolate Inhalation Solution 100μg: Glycopyrrolate Inhalation Solution 100μg via eFlow, once daily</description>
          </group>
          <group group_id="O4">
            <title>Glycopyrrolate Inhalation Solution 200μg</title>
            <description>Glycopyrrolate Inhalation Solution 200μg via e-flow nebulizer, once daily
Glycopyrrolate Inhalation Solution 200μg: Glycopyrrolate Inhalation Solution 200μg via eFlow, once daily</description>
          </group>
          <group group_id="O5">
            <title>Glycopyrrolate Inhalation Solution 400μg</title>
            <description>Glycopyrrolate Inhalation Solution 400μg via e-flow nebulizer, once daily
Glycopyrrolate Inhalation Solution 400μg: Glycopyrrolate Inhalation Solution 400μg via eFlow, once daily</description>
          </group>
          <group group_id="O6">
            <title>Placebo 0.5mL</title>
            <description>Placebo 0.5mL via e-flow nebulizer, once daily
Placebo 0.5mL: Placebo 0.5mL via eFlow, once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Who Died, Number of Subjects With Treatment Emergent SAEs, Number of Subjects Who Discontinued Due to AE</title>
          <description>AE's are defined as existing conditions which worsen or events which occur during the course of the clinical trial after treatment</description>
          <population>all subjects who received at least one dose of study drug were included in the safety analysis</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
                <count group_id="O2" value="38"/>
                <count group_id="O3" value="37"/>
                <count group_id="O4" value="37"/>
                <count group_id="O5" value="37"/>
                <count group_id="O6" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>subjects who died</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>subjects with treatment emergent SAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Subjects whodiscontinued due to an AE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>subjects with treatment emergent AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="14"/>
                    <measurement group_id="O3" value="17"/>
                    <measurement group_id="O4" value="15"/>
                    <measurement group_id="O5" value="13"/>
                    <measurement group_id="O6" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Clinically Significant Abnormal Vital Signs Reported During the Study</title>
        <description>Vital signs were measured at screening and at each Treatment Visit pre-dose (within 30 minutes prior to dose); post-dose at 30 minutes and 1, 2, 4, 8, 12 and 24 hours; and then at the post study assessment.</description>
        <time_frame>0-24 h</time_frame>
        <population>all subjects who received at least one does of study drug were included in the safety analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Glycopyrrolate Inhalation Solution12.5μg</title>
            <description>Glycopyrrolate Inhalation Solution12.5μg via e-flow nebulizer, once daily
Glycopyrrolate Inhalation Solution12.5μg: Glycopyrrolate Inhalation Solution12.5μg via eFlow, once daily</description>
          </group>
          <group group_id="O2">
            <title>Glycopyrrolate Inhalation Solution 50μg</title>
            <description>Glycopyrrolate Inhalation Solution 50mg via e-flow nebulizer, once daily
Glycopyrrolate Inhalation Solution 50μg: Glycopyrrolate Inhalation Solution 50μg via eFlow, once daily</description>
          </group>
          <group group_id="O3">
            <title>Glycopyrrolate Inhalation Solution 100μg</title>
            <description>Glycopyrrolate Inhalation Solution 100μg via e-flow nebulizer, once daily
Glycopyrrolate Inhalation Solution 100μg: Glycopyrrolate Inhalation Solution 100μg via eFlow, once daily</description>
          </group>
          <group group_id="O4">
            <title>Glycopyrrolate Inhalation Solution 200μg</title>
            <description>Glycopyrrolate Inhalation Solution 200μg via e-flow nebulizer, once daily
Glycopyrrolate Inhalation Solution 200μg: Glycopyrrolate Inhalation Solution 200μg via eFlow, once daily</description>
          </group>
          <group group_id="O5">
            <title>Glycopyrrolate Inhalation Solution 400μg</title>
            <description>Glycopyrrolate Inhalation Solution 400μg via e-flow nebulizer, once daily
Glycopyrrolate Inhalation Solution 400μg: Glycopyrrolate Inhalation Solution 400μg via eFlow, once daily</description>
          </group>
          <group group_id="O6">
            <title>Placebo 0.5mL</title>
            <description>Placebo 0.5mL via e-flow nebulizer, once daily
Placebo 0.5mL: Placebo 0.5mL via eFlow, once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Clinically Significant Abnormal Vital Signs Reported During the Study</title>
          <description>Vital signs were measured at screening and at each Treatment Visit pre-dose (within 30 minutes prior to dose); post-dose at 30 minutes and 1, 2, 4, 8, 12 and 24 hours; and then at the post study assessment.</description>
          <population>all subjects who received at least one does of study drug were included in the safety analysis</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
                <count group_id="O2" value="38"/>
                <count group_id="O3" value="37"/>
                <count group_id="O4" value="37"/>
                <count group_id="O5" value="37"/>
                <count group_id="O6" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Clinically Significant Abnormal Laboratory Results Reported During the Study</title>
        <description>Clinical safety lab parameters were collected at screening and at the post study assessment. Any laboratory values that were out of range of normal reference values were evaluated by the Investigators.</description>
        <time_frame>Day -14, Day 69</time_frame>
        <population>all subjects who received at least one dose of study drug were included in the safety analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Glycopyrrolate Inhalation Solution12.5μg</title>
            <description>Glycopyrrolate Inhalation Solution12.5μg via e-flow nebulizer, once daily
Glycopyrrolate Inhalation Solution12.5μg: Glycopyrrolate Inhalation Solution12.5μg via eFlow, once daily</description>
          </group>
          <group group_id="O2">
            <title>Glycopyrrolate Inhalation Solution 50μg</title>
            <description>Glycopyrrolate Inhalation Solution 50mg via e-flow nebulizer, once daily
Glycopyrrolate Inhalation Solution 50μg: Glycopyrrolate Inhalation Solution 50μg via eFlow, once daily</description>
          </group>
          <group group_id="O3">
            <title>Glycopyrrolate Inhalation Solution 100μg</title>
            <description>Glycopyrrolate Inhalation Solution 100μg via e-flow nebulizer, once daily
Glycopyrrolate Inhalation Solution 100μg: Glycopyrrolate Inhalation Solution 100μg via eFlow, once daily</description>
          </group>
          <group group_id="O4">
            <title>Glycopyrrolate Inhalation Solution 200μg</title>
            <description>Glycopyrrolate Inhalation Solution 200μg via e-flow nebulizer, once daily
Glycopyrrolate Inhalation Solution 200μg: Glycopyrrolate Inhalation Solution 200μg via eFlow, once daily</description>
          </group>
          <group group_id="O5">
            <title>Glycopyrrolate Inhalation Solution 400μg</title>
            <description>Glycopyrrolate Inhalation Solution 400μg via e-flow nebulizer, once daily
Glycopyrrolate Inhalation Solution 400μg: Glycopyrrolate Inhalation Solution 400μg via eFlow, once daily</description>
          </group>
          <group group_id="O6">
            <title>Placebo 0.5mL</title>
            <description>Placebo 0.5mL via e-flow nebulizer, once daily
Placebo 0.5mL: Placebo 0.5mL via eFlow, once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Clinically Significant Abnormal Laboratory Results Reported During the Study</title>
          <description>Clinical safety lab parameters were collected at screening and at the post study assessment. Any laboratory values that were out of range of normal reference values were evaluated by the Investigators.</description>
          <population>all subjects who received at least one dose of study drug were included in the safety analysis</population>
          <units>number of events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
                <count group_id="O2" value="38"/>
                <count group_id="O3" value="37"/>
                <count group_id="O4" value="37"/>
                <count group_id="O5" value="37"/>
                <count group_id="O6" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Clinically Significant ECG Parameters Reported During the Study</title>
        <description>ECGs were recorded at screening and at each study treatment visit pre-dose (within 30 minutes prior to dose); post-dose at 30 minutes and 1, 2, 4, 8, 12 and 24 hours; and then at the post study assessment.</description>
        <time_frame>0 to 24h</time_frame>
        <population>all subjects who received at least one dose of study drug were included in the safety analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Glycopyrrolate Inhalation Solution12.5μg</title>
            <description>Glycopyrrolate Inhalation Solution12.5μg via e-flow nebulizer, once daily
Glycopyrrolate Inhalation Solution12.5μg: Glycopyrrolate Inhalation Solution12.5μg via eFlow, once daily</description>
          </group>
          <group group_id="O2">
            <title>Glycopyrrolate Inhalation Solution 50μg</title>
            <description>Glycopyrrolate Inhalation Solution 50mg via e-flow nebulizer, once daily
Glycopyrrolate Inhalation Solution 50μg: Glycopyrrolate Inhalation Solution 50μg via eFlow, once daily</description>
          </group>
          <group group_id="O3">
            <title>Glycopyrrolate Inhalation Solution 100μg</title>
            <description>Glycopyrrolate Inhalation Solution 100μg via e-flow nebulizer, once daily
Glycopyrrolate Inhalation Solution 100μg: Glycopyrrolate Inhalation Solution 100μg via eFlow, once daily</description>
          </group>
          <group group_id="O4">
            <title>Glycopyrrolate Inhalation Solution 200μg</title>
            <description>Glycopyrrolate Inhalation Solution 200μg via e-flow nebulizer, once daily
Glycopyrrolate Inhalation Solution 200μg: Glycopyrrolate Inhalation Solution 200μg via eFlow, once daily</description>
          </group>
          <group group_id="O5">
            <title>Glycopyrrolate Inhalation Solution 400μg</title>
            <description>Glycopyrrolate Inhalation Solution 400μg via e-flow nebulizer, once daily
Glycopyrrolate Inhalation Solution 400μg: Glycopyrrolate Inhalation Solution 400μg via eFlow, once daily</description>
          </group>
          <group group_id="O6">
            <title>Placebo 0.5mL</title>
            <description>Placebo 0.5mL via e-flow nebulizer, once daily
Placebo 0.5mL: Placebo 0.5mL via eFlow, once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Clinically Significant ECG Parameters Reported During the Study</title>
          <description>ECGs were recorded at screening and at each study treatment visit pre-dose (within 30 minutes prior to dose); post-dose at 30 minutes and 1, 2, 4, 8, 12 and 24 hours; and then at the post study assessment.</description>
          <population>all subjects who received at least one dose of study drug were included in the safety analysis</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
                <count group_id="O2" value="38"/>
                <count group_id="O3" value="37"/>
                <count group_id="O4" value="37"/>
                <count group_id="O5" value="37"/>
                <count group_id="O6" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Subjects With Treatment Emergent AEs</title>
        <description>AE's are defined as existing conditions which worsen or events which occur during the course of the clinical trial after treatment</description>
        <time_frame>Day 69 (includes dosing Day 1, washout Day 12, safety follow up Day 69)</time_frame>
        <population>all subjects who received at least one dose of study drug were included in the safety analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Glycopyrrolate Inhalation Solution12.5μg</title>
            <description>Glycopyrrolate Inhalation Solution12.5μg via e-flow nebulizer, once daily
Glycopyrrolate Inhalation Solution12.5μg: Glycopyrrolate Inhalation Solution12.5μg via eFlow, once daily</description>
          </group>
          <group group_id="O2">
            <title>Glycopyrrolate Inhalation Solution 50μg</title>
            <description>Glycopyrrolate Inhalation Solution 50mg via e-flow nebulizer, once daily
Glycopyrrolate Inhalation Solution 50μg: Glycopyrrolate Inhalation Solution 50μg via eFlow, once daily</description>
          </group>
          <group group_id="O3">
            <title>Glycopyrrolate Inhalation Solution 100μg</title>
            <description>Glycopyrrolate Inhalation Solution 100μg via e-flow nebulizer, once daily
Glycopyrrolate Inhalation Solution 100μg: Glycopyrrolate Inhalation Solution 100μg via eFlow, once daily</description>
          </group>
          <group group_id="O4">
            <title>Glycopyrrolate Inhalation Solution 200μg</title>
            <description>Glycopyrrolate Inhalation Solution 200μg via e-flow nebulizer, once daily
Glycopyrrolate Inhalation Solution 200μg: Glycopyrrolate Inhalation Solution 200μg via eFlow, once daily</description>
          </group>
          <group group_id="O5">
            <title>Glycopyrrolate Inhalation Solution 400μg</title>
            <description>Glycopyrrolate Inhalation Solution 400μg via e-flow nebulizer, once daily
Glycopyrrolate Inhalation Solution 400μg: Glycopyrrolate Inhalation Solution 400μg via eFlow, once daily</description>
          </group>
          <group group_id="O6">
            <title>Placebo 0.5mL</title>
            <description>Placebo 0.5mL via e-flow nebulizer, once daily
Placebo 0.5mL: Placebo 0.5mL via eFlow, once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects With Treatment Emergent AEs</title>
          <description>AE's are defined as existing conditions which worsen or events which occur during the course of the clinical trial after treatment</description>
          <population>all subjects who received at least one dose of study drug were included in the safety analysis</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
                <count group_id="O2" value="38"/>
                <count group_id="O3" value="37"/>
                <count group_id="O4" value="37"/>
                <count group_id="O5" value="37"/>
                <count group_id="O6" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.0"/>
                    <measurement group_id="O2" value="36.8"/>
                    <measurement group_id="O3" value="45.9"/>
                    <measurement group_id="O4" value="40.5"/>
                    <measurement group_id="O5" value="35.1"/>
                    <measurement group_id="O6" value="37.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>0-69 days</time_frame>
      <desc>AEs are defined as existing conditions which worsen or events which occur during the course of the clinical trial after treatment</desc>
      <group_list>
        <group group_id="E1">
          <title>Glycopyrrolate Inhalation Solution12.5μg</title>
          <description>Glycopyrrolate Inhalation Solution12.5μg via e-flow nebulizer, once daily
Glycopyrrolate Inhalation Solution12.5μg: Glycopyrrolate Inhalation Solution12.5μg via eFlow, once daily</description>
        </group>
        <group group_id="E2">
          <title>Glycopyrrolate Inhalation Solution 50μg</title>
          <description>Glycopyrrolate Inhalation Solution 50mg via e-flow nebulizer, once daily
Glycopyrrolate Inhalation Solution 50μg: Glycopyrrolate Inhalation Solution 50μg via eFlow, once daily</description>
        </group>
        <group group_id="E3">
          <title>Glycopyrrolate Inhalation Solution 100μg</title>
          <description>Glycopyrrolate Inhalation Solution 100μg via e-flow nebulizer, once daily
Glycopyrrolate Inhalation Solution 100μg: Glycopyrrolate Inhalation Solution 100μg via eFlow, once daily</description>
        </group>
        <group group_id="E4">
          <title>Glycopyrrolate Inhalation Solution 200μg</title>
          <description>Glycopyrrolate Inhalation Solution 200μg via e-flow nebulizer, once daily
Glycopyrrolate Inhalation Solution 200μg: Glycopyrrolate Inhalation Solution 200μg via eFlow, once daily</description>
        </group>
        <group group_id="E5">
          <title>Glycopyrrolate Inhalation Solution 400μg</title>
          <description>Glycopyrrolate Inhalation Solution 400μg via e-flow nebulizer, once daily
Glycopyrrolate Inhalation Solution 400μg: Glycopyrrolate Inhalation Solution 400μg via eFlow, once daily</description>
        </group>
        <group group_id="E6">
          <title>Placebo 0.5mL</title>
          <description>Placebo 0.5mL via e-flow nebulizer, once daily
Placebo 0.5mL: Placebo 0.5mL via eFlow, once daily</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 13.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>groin pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 13.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="39"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="37"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="37"/>
                <counts group_id="E5" subjects_affected="10" subjects_at_risk="37"/>
                <counts group_id="E6" subjects_affected="10" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>skin injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>headache</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="39"/>
                <counts group_id="E2" events="6" subjects_affected="5" subjects_at_risk="38"/>
                <counts group_id="E3" events="8" subjects_affected="5" subjects_at_risk="37"/>
                <counts group_id="E4" events="9" subjects_affected="7" subjects_at_risk="37"/>
                <counts group_id="E5" events="8" subjects_affected="6" subjects_at_risk="37"/>
                <counts group_id="E6" events="5" subjects_affected="4" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>cough</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="39"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="38"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="37"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="37"/>
                <counts group_id="E5" events="4" subjects_affected="3" subjects_at_risk="37"/>
                <counts group_id="E6" events="5" subjects_affected="5" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>dyspnoea</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="39"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="38"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E4" events="2" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E6" events="3" subjects_affected="2" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>In the event the Study is part of a multi-center study, the first publication of the results of the Study shall be made in conjunction with the results of other participating study sites as a multi-center publication; provided however, if a multi-center publication is not forthcoming within twenty-four (24) months following completion of the Study at all sites, Institution and Investigator shall be free to publish.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Respiratory Medical Director</name_or_title>
      <organization>Sunovion Pharmaceuticals Inc.</organization>
      <phone>1-866-503-6351</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

